A global survey of potential acceptance of a COVID-19 vaccine

Jeffrey V Lazarus, Scott C Ratzan, Adam Palayew, Lawrence O Gostin, Heidi J Larson, Kenneth Rabin, Spencer Kimball, Ayman El-Mohandes, Jeffrey V Lazarus, Scott C Ratzan, Adam Palayew, Lawrence O Gostin, Heidi J Larson, Kenneth Rabin, Spencer Kimball, Ayman El-Mohandes

Abstract

Several coronavirus disease 2019 (COVID-19) vaccines are currently in human trials. In June 2020, we surveyed 13,426 people in 19 countries to determine potential acceptance rates and factors influencing acceptance of a COVID-19 vaccine. Of these, 71.5% of participants reported that they would be very or somewhat likely to take a COVID-19 vaccine, and 48.1% reported that they would accept their employer's recommendation to do so. Differences in acceptance rates ranged from almost 90% (in China) to less than 55% (in Russia). Respondents reporting higher levels of trust in information from government sources were more likely to accept a vaccine and take their employer's advice to do so.

Conflict of interest statement

The authors declare no competing interests.

Figures

Extended Data Fig. 1. ‘If a COVID-19…
Extended Data Fig. 1. ‘If a COVID-19 vaccine is proven safe and effective and is available, I will take it’.
Numbers above the bars represent the percent of respondents in each country who responded positively to the question ‘If a COVID-19 vaccine is proven safe and effective and is available, I will take it’.

References

    1. MacDonald NE. & SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33:4161–4164. doi: 10.1016/j.vaccine.2015.04.036.
    1. Karafillakis E, Larson HJ. & ADVANCE Consortium. The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations. Vaccine. 2017;35:4840–4850. doi: 10.1016/j.vaccine.2017.07.061.
    1. Cobos Muñoz D, Monzón Llamas L, Bosch-Capblanch X. Exposing concerns about vaccination in low- and middle-income countries: a systematic review. Int. J. Public Health. 2015;60:767–780. doi: 10.1007/s00038-015-0715-6.
    1. European Parliament. European Parliament resolution of 19 April 2018 on vaccine hesitancy and drop in vaccination rates in Europe (2017/2951 RSP). (2018).
    1. Larson HJ, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. Vaccine. 2014;32:2150–2159. doi: 10.1016/j.vaccine.2014.01.081.
    1. Lane S, MacDonald NE, Marti M, Dumolard L. Vaccine hesitancy around the globe: analysis of three years of WHO/UNICEF Joint Reporting Form data—2015–2017. Vaccine. 2018;36:3861–3867. doi: 10.1016/j.vaccine.2018.03.063.
    1. Enserink, M. & Cohen, J. Fact-checking Judy Mikovits, the controversial virologist attacking Anthony Fauci in a viral conspiracy video. Science (2020).
    1. Cornwall W. Officials gird for a war on vaccine misinformation. Science. 2020;369:14–19. doi: 10.1126/science.369.6499.14.
    1. Fadda M, Albanese E, Suggs LS. When a COVID-19 vaccine is ready, will we all be ready for it? Int. J. Public Health. 2020;65:711–712. doi: 10.1007/s00038-020-01404-4.
    1. Larson HJ, et al. Measuring trust in vaccination: a systematic review. Hum. Vaccines Immunother. 2018;14:1599–1609. doi: 10.1080/21645515.2018.1459252.
    1. Biasio LR. Vaccine hesitancy and health literacy. Hum. Vaccines Immunother. 2017;13:701–702. doi: 10.1080/21645515.2016.1243633.
    1. Thomson A, Vallée-Tourangeau G, Suggs LS. Strategies to increase vaccine acceptance and uptake: from behavioral insights to context-specific, culturally-appropriate, evidence-based communications and interventions. Vaccine. 2018;36:6457–6458. doi: 10.1016/j.vaccine.2018.08.031.
    1. European Centre for Disease Prevention and Control. Catalogue of interventions addressing vaccine hesitancy. (2017).
    1. Lugo NR. Will carrots or sticks raise influenza immunization rates of health care personnel? Am. J. Infect. Control. 2007;35:1–6. doi: 10.1016/j.ajic.2006.10.004.
    1. Hovland CI, Weiss W. The influence of source credibility on communication effectiveness. Public Opin. Q. 1951;15:635. doi: 10.1086/266350.
    1. Siegrist M, Zingg A. The role of public trust during pandemics: implications for crisis communication. Eur. Psychol. 2014;19:23–32. doi: 10.1027/1016-9040/a000169.
    1. Quinn SC, et al. Exploring communication, trust in government, and vaccination intention later in the 2009 H1N1 pandemic: results of a national survey. Biosecurity Bioterrorism. 2013;11:96–106. doi: 10.1089/bsp.2012.0048.
    1. Shore DA. Communicating in times of uncertainty: the need for trust. J. Health Commun. 2003;8:13–14. doi: 10.1080/713851977.
    1. Mahase E. Covid-19: Oxford researchers halt vaccine trial while adverse reaction is investigated. BMJ. 2020;370:m3525. doi: 10.1136/bmj.m3525.
    1. Burki, T. K. The Russian vaccine for COVID-19. Lancet Respir. Med. 10.1016/S2213-2600(20)30402-1 (2020).
    1. Lazarus JV, et al. COVID-SCORE: a global survey to assess public perceptions of government responses to COVID-19 (COVID-SCORE-10) PLoS ONE. 2020;15:e0240011. doi: 10.1371/journal.pone.0240011.
    1. Johns Hopkins Coronavirus Resource Center. COVID-19 dashboard. (2020).

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する